ConductScience.org, home

Comparison · NCT02622724-deaths

FP-1201-lyo 10 μg vs Placebo: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. FP-1201-lyo 10 μg vs Placebo: deaths from any cause. Trial comparisons, record NCT02622724-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02622724-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3540.2810.435wilson
Risk in group 20.3490.2780.427wilson
Risk difference, group 1 minus group 20.00548-0.1020.113newcombe hybrid score
Risk ratio, group 1 over group 21.020.7451.38log
Odds ratio, group 1 over group 21.020.6351.65log
Number needed to harm, for one more death from any cause on FP-1201-lyo 10 μg than on Placebo182from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1FP-1201-lyo 10 μg
FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.~Interferon beta-1a: Investigational drug
51144EG000
Group 2Placebo
Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.~Placebo: Placebo for investigational drug
53152EG001

Harm

What it counts
Total, all-cause mortality
Time frame
The Adverse Event (AE) reporting period extended up to study Day 28. In accordance with the protocol, the investigators reported AEs occurring after Day 28 only if the investigator considered a causal relationship with the study drug. All deaths were reported as SAEs throughout the study, up until Day 360.

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
NCT number
NCT02622724
Phases
PHASE3
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Interferon beta-1a, Placebo
Lead sponsor
Faron Pharmaceuticals Ltd
Results first posted
2020-03-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02622724-deaths